There are at present multiple small molecule agents/drugs that have been developed to inhibit c-MET, including crizotinib (XALKORI®) that is FDA approved for the treatment of ALK or ROS1 mutant expressing non-small cell lung cancer. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.